

**Wanbury Limited**

**Regd. Office :** BSEL Tech Park, B-wing  
10<sup>th</sup> Floor, Sector-30 A,  
Opp. Vashi Railway Station,  
Vashi Navi Mumbai 400 703  
Maharashtra, INDIA  
Tel. : +91-22-6794 2222  
+91-22-7196 3222  
CIN L51900MH1988PLC048455  
Email : [info@wanbury.com](mailto:info@wanbury.com)  
Website : [www.wanbury.com](http://www.wanbury.com)

May 29, 2025

To The Manager – Listing BSE Limited PJ. Towers, Dalal Street Mumbai – 400 001. <b>Script Code: 524212</b>	To The Manager – Listing National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051. <b>Script Code: WANBURY</b>
---	--

Dear Sir/Madam,

**Sub: Press release on Q4 & FY25 Financial Results**

Please find attached herewith copy of press release on Financial Results for the Quarter & Year ended 31<sup>st</sup> March, 2025.

This is for your information and record.

Thanking you.

Yours faithfully,  
For Wanbury Ltd

Jitendra J. Gandhi  
Company Secretary





**Strong Operational Efficiency led:**

**EBITDA surging 65%, PAT up by 154%**

27<sup>th</sup> May, 2025, MUMBAI: Wanbury Ltd, a pharmaceutical company with a presence in the global API market and domestic branded formulations, has announced its financial results for the quarter and year ended 31<sup>st</sup> March, 2025.

**Consolidated Q4 FY25 Financial Highlights**

**(Rs in Crore)**

Particulars	Q4 FY25	Q4 FY24	Y-o-Y	Q3 FY25	Q-o-Q	FY25**	FY24	Y-o-Y
Revenue from Operations	172.0	139.8	23%	133.5	29%	599.5	577.7	4%
EBITDA (incl. other income)	31.5	19.1	65%	14.8	113%	79.8	73.0	9%
EBITDA Margin (%)	18.3%	13.7%	464 bps	11.1%	721 bps	13.3%	12.6%	68 bps
PAT	20.3	8.0*	154%	1.2	1592%	30.5	30.4*	0%
PAT Margin (%)	11.80%	5.72%	608 bps	0.90%	1090 bps	5.1%	5.3%	-17 bps

**Note:**

\*The financial highlights presented above reflect Adjusted PAT for Q4FY24, which excludes a non-cash exceptional item of ₹25.55 crore as disclosed in the income statement

\*\*During the year, both the manufacturing facilities of the Holding Company were not fully functional for about 40 days for scheduled upgradation & renovation. As a result, they were not fully utilised throughout the entire year, which affected Group's revenues and profitability accordingly.

**Financial Highlights:**

**For the quarter ended as on 31<sup>st</sup> March 2025:**

- Revenue from operations for Q4FY25 stood at ₹ 172.0 crore, up from ₹ 139.8 crore in Q4FY24, reflecting a YoY growth of 23%. This growth was driven by higher sales volumes in key API products such as Metformin & Sertraline, supported by increased production capacity.
- EBITDA (including other income) for the quarter stood at ₹ 31.5 crore (EBITDA Margin 18.3%), compared to ₹ 19.1 crore in Q4FY24, registering a growth of 65%. This performance was driven by sales volume growth, operational efficiency such as productivity enhancements, yield improvement, better solvent recoveries, lower costs due to backward integration of key API products such as Sertraline duly supported by recent plant upgradation
- PAT for the quarter stood at ₹ 20.3 crore (PAT Margin 11.8%), compared to ₹ 8 crore in Q4FY24, registering a robust growth of 154%





### Other Key Highlights:

- **Successfully Refinancing the Debt at a substantial lower interest rate**

Wanbury Limited has successfully refinanced its ₹95 crore debt which was originally issued at 21% interest in July 2023 to NEO AIF and associates.

- Company raised ₹ 175 cr. by allotment of Unlisted, Secured, Redeemable Non-Convertible Debentures ("NCDs") under Tranche I from Emerging India Credit Opportunities Fund II, linked to Investec Capital Services
- The fund is utilised towards re-financing of its existing high cost debt to lower interest rate of 12.5% for up to ₹150 crore, covering ₹90 crore from NEO AIF and ₹60 crore from other lenders
- The remaining funds will support working capital and capex
- The loan tenure is 5 years, with an average maturity of 3.25 years and a 9-month moratorium

- **Launched two new products for Formulation (Branded generic) - Branded Hematinic Iron tablets Wanbury C-RED and for API (Bulk Drug) - Ketamine Hydrochloride.**

- **Wanbury C-Red** - Leveraging its past strong equity in the gynaecology segment with legacy brands like *C Pink*, Wanbury is re-entering the space with Wanbury C-RED, its an iron supplement, which helps improving haemoglobin in the blood of individuals especially during pregnancy.
- **Ketamine Hydrochloride** - Ketamine is used to promote sleep before & during surgeries. A controlled substance with significant regulatory and manufacturing barriers It has annual demand of over 200 tons for both human and veterinary market. The Ketamine is developed by a unique cost competitive process & quality product by In - house R&D team in compliance with all the major pharmacopeia such as USP & EP

- **The Tanuku manufacturing facility has successfully completed an ANVISA (Brazil FDA) inspection with zero observations. Inspection conducted from December 16 to 20, 2024, confirmed full compliance with CGMP(Current Good Manufacturing Practices) standards.**

- **Initiated a digital transformation journey with plans to implement SAP S/4 HANA Private Cloud. This strategic move is aimed at enhancing critical business functions such as Finance, Sales, Production, Quality, Material Management, and Compliance. Once deployed, it will enable integrated operations and improve agility in responding to market dynamics and regulatory changes. The implementation is targeted for completion in the H1 2025-26.**







- *Commenting on the performance, Mr. Mohan Rayana, Director of Wanbury Ltd., said, "We are pleased to report the FY25 results, demonstrating resilience despite the shutdown of our Tanuku facility for scheduled major upgradation and capacity expansion for 40 days adversely impacting profitability and revenue during the year.*

We continue to strengthen our API portfolio by expanding capacity and broadening our geographic presence, with plans to accelerate growth through near term launch of three new APIs. The successful completion of the ANVISA audit at our Tanuku facility in December 2024, with no observations, enabling to solidify our position in the Brazilian market. With recent upgrades and capacity expansion at Tanuku, we are well-positioned to drive enhanced productivity, cost efficiency, scalability, and revenue growth.

In Domestic Formulations, our focus remains on enhancing profitability, expanding our product portfolio, and increasing market share. To support this growth, Wanbury Limited has appointed Mr. Rashesh Patel as Corporate Director – India Formulation Business, leveraging his four decades of experience in scaling businesses and driving market expansion. Additionally, Mr. Pallavur Sankar Dass Vaidyanathan and Mr. Manoj Gursahani have joined as Additional (Non-Executive Independent) Directors, bringing strategic leadership and industry expertise to strengthen Wanbury's business expansion, governance, and market positioning.

With a strong leadership team, strategic expansions, and a renewed growth trajectory, Wanbury Limited is well-positioned to drive sustainable profitability and market leadership in the coming quarters."

#### About Wanbury Ltd.

Established in 1988, listed on the National Stock Exchange of India Ltd. (Symbol: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The Company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine and various other products in pipeline. The Company's clients include some of the leading global generic players.

In formulations, the Company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory & analgesics.

For more details on Wanbury Ltd.: <https://www.wanbury.com/>





For further information please contact:

Jitendra J. Gandhi  
Company Secretary,  
Wanbury Limited  
BSEL Techpark, B' Wing, 10th Floor,  
Sector 30-A, Opp. Vashi Railway Station,  
Vashi, Navi Mumbai - 400703, India.  
Tel: +91-22-6794 2222  
Email: [jitendra.gandhi@wanbury.com](mailto:jitendra.gandhi@wanbury.com)

Hanishi Shah / Anand Venugopal  
Adfactors PR  
Oasis Complex, Kamala Mills Compound,  
City Hall, Pandurang Budhkar Marg, Lower  
Parel West, Mumbai - 400021  
Tel: +91 9619059339 / +91 7021852071  
Email: [hanishi.shah@adfactorspr.com](mailto:hanishi.shah@adfactorspr.com)  
[anand.venugopal@adfactorspr.com](mailto:anand.venugopal@adfactorspr.com)

**Disclaimer:**

*This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.*

